首页 | 本学科首页   官方微博 | 高级检索  
检索        


Bicarbon valve - European multicenter clinical evaluation
Authors:JB Borman  WGB Brands  L Camilleri  M Cotrufo  W Daenen  I Gandjbakhch  C Infantes  A Khayat  F Laborde  A Pellegrini  A Piwnica  B Reichart  R Sharony  R Walesby  H Warembourg
Institution:

a Bikur Cholim Hospital, Jerusalem, Israel

b Hadassah University Hospital, Jerusalem, Israel

c Medisch Centrum de Klokkenberg, Breda, The Netherlands

d Centre Hospitalier Universitaire, Clermond Ferrand, France

e Azienda Ospedaliera Ospedale Monaldi, Napoli, Italy

f Gasthuisberg University Hospital, Leuven, Belgium

g Hopital La Pitié Salpetrière, Paris, France

h Hospital Virgin Macarena, Seville, Spain

i Hôpital Côte de Nacre, Caen, France

j L'Institut Mutualiste Montsouris, Paris, France

k Ospedale Niguarda Ca Granda, Milan, Italy

l Hôpital Lariboisière, Paris, France

m Grosshadern Klinikum, Munich, Germany

n Carmel Medical Center, Haifa, Israel

o London Chest Hospital, London, UK

p Hôpital Cardiologique, Lille, France

Abstract:Objective: Fifteen collaborating centers in eight countries present their pooled experience with the new Bicarbon™ bileaflet valve. Methods: Between 4/90 and 4/96, 1351 patients, 806 males and 545 females, aged 10 to 83, mean 58.4±12.4, underwent valve implantation. Operations: AVR, 726; MVR, 475; DVR, 150. Additional procedures: CABG, 211; TV repair, 64; other, 152. Results: Mortality: 67 early (seven valve related) and 56 late (40 valve related). Valve thrombosis: six obstructive, three non-obstructive; embolism: nine major cerebral, 37 other. Major bleeding: 29. Hemolysis: two clinically significant. Non-structural dysfunction: 24 paravalvular leaks, one leaflet interference. No structural failure! Endocarditis: 24. Reoperation 48: 22 non-structural dysfunctions, 14 endocarditis, seven thrombosis and embolism, five other. Estimated 5-year freedom from valve-related deaths is 97.2% for AVR and 92.4% for MVR; 4-year freedom from valve related deaths for DVR is 90.5%. Mean calculated NYHA improvement is 1.24. Conclusions: The Bicarbon mechanical prosthesis is well designed, durable, has good hemodynamic features and an acceptably low incidence of complications.
Keywords:Bicarbon valve  Heart valve replacement  Bileaflet hinged mechanical prosthesis  Results
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号